TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Taysha Gene Therapies Inc (TSHA) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this moment. While there are positive developments in the company's financials and analyst ratings, the lack of significant near-term catalysts, overbought technical indicators, and insider selling activity suggest a cautious approach.
The stock shows bullish momentum with MACD positively expanding and moving averages in a bullish sequence (SMA_5 > SMA_20 > SMA_200). However, the RSI of 83.541 indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at 5.729 and 6.173, with support at 5.011 and 4.293.
Hedge funds are significantly increasing their buying activity (649.63% increase).
Analyst Whitney Ijem raised the price target to $17, citing positive trial updates and upcoming data releases.
Financial performance shows strong revenue growth (171.27% YoY) and improved net income (-48.26% YoY).
Insiders are heavily selling, with a 11823.54% increase in selling activity over the last month.
RSI indicates the stock is overbought, which could lead to a near-term price correction.
No recent news or event-driven catalysts to support immediate upward momentum.
In Q4 2025, revenue increased by 171.27% YoY to $5,485,000, net income improved by 48.26% YoY to -$27,851,000, and EPS increased by 14.29% YoY to -0.08. Gross margin remains strong at 100%.
Canaccord analyst Whitney Ijem reiterated a Buy rating and raised the price target from $14 to $17, citing positive trial updates and upcoming data releases expected in Q2 2026.
